top of page
The Sound of Evolution
Lisinopril
賴諾普利
Mechanism of action:
Lisinopril 是一種非硫醇類血管張力素轉化酶抑制劑（non-sulfhydryl angiotensin-converting enzyme inhibitor）。血管張力素轉化酶（angiotensin-converting enzyme）原本負責將血管張力素 I（angiotensin I）轉換為血管張力素 II（angiotensin II）。血管張力素 II 能夠造成血管收縮（升高血壓）、刺激腎上腺分泌醛固酮（aldosterone）增加鈉離子與水的保留、刺激交感神經、促進心肌與血管平滑肌肥厚。Lisinopril 抑制血管張力素轉化酶後，血管張力素 II 便會下降，使血壓下降、心臟後負荷減輕，並可降低緩激肽（bradykinin）的分解而促進血管擴張。
Reference(s):
1. Thomson AH et al. (1989). Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension. Br J Clin Pharmacol.
2. Beermann B et al. (1988). Pharmacokinetics of lisinopril. Am J Med.
3. Goa KL et al. (1996). Lisinopril: a review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs.
bottom of page